Lilly Reduces Price of Zepbound Vials
- Zepbound single-dose vials are now available at lower prices on LillyDirect.
- Starting dose of 2.5 mg costs $299 per month, 5 mg at $399, and other doses at $449.
- Zepbound is an injectable prescription medicine containing tirzepatide.
- It is not known if Zepbound is safe for children.
Price Reduction
Eli Lilly and Company has announced a price reduction for Zepbound (tirzepatide) single-dose vials, available through LillyDirect. This move aims to lower out-of-pocket costs for obesity patients in the U.S.
Pricing Details
With a valid prescription, the starting dose of Zepbound (2.5 mg) is priced at $299 per month. The 5 mg dose is available for $399 per month, while all other approved doses cost $449 per month under the Zepbound Self Pay Journey Program.
Access and Treatment
Zepbound is an injectable prescription medicine designed to help adults with obesity, or those with overweight and weight-related medical issues, to lose and maintain weight. It may also aid adults with moderate-to-severe obstructive sleep apnea (OSA) and obesity in improving their OSA.
Usage Guidelines
Zepbound contains tirzepatide and should not be used with other tirzepatide-containing products or GLP-1 receptor agonist medicines. Its safety and effectiveness for children remain unknown.
Source: Lilly